About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, October 3rd, 2012

The QualityStocks
Daily Stock List

graphic
graphic

Onteco Corp. (ONTC)

OTCPicks, Penny Stock Rumble, PennyTrader Publisher, Stock Exploder, and Pumps and Dumps, reported recently on Onteco Corp. (ONTC). PSSMS Newsletter, Greenbackers, SmallCapInvestorDaily, OTCtipReporter, PennyStockScholar, Stockdigest Report, Michael Stone, PickPennyStocks, Canadian Microcap Report, Research Driven Investor reported earlier, and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Founded in 2007, Onteco Corp. focuses on investing in and developing proprietary technologies that target alternative energy marketplaces domestically and internationally. Their current investment focus is within the Energy Saving Lighting Industry. Consequently, they acquired NexPhase Lighting, Inc., in February of 2011. Onteco has their corporate headquarters in Aventura, Florida. The Company's shares trade on the OTCQB.

By way of their subsidiaries, joint ventures, and business partners, Onteco's mission is to continue to invest in, develop, nurture, and bring to market, innovative, practical, and cost-effective solutions to everyday environmental and alternative energy needs. The Company's NexPhase Lighting designs and develops proprietary high quality LED (Light-Emitting Diode) lighting fixtures and control systems for commercial applications.

All NexPhase lighting products incorporate their proprietary "NexSense Technology™". NexSense control systems use a unique, "patent pending" wireless protocol. It provides for substantial reduction in architecture and infrastructure installation cost in commercial applications, and significantly reduced maintenance and ongoing operation costs.

In September, Onteco announced that they entered into a Letter of Intent (LOI) to acquire all of the issued and outstanding shares of Cyber Centers International Corp., a privately-held Florida corporation, (CCI), in exchange for the issuance of a number of shares of common stock of the Company. CCI is in the business of interactive money games.

Today, Onteco provided additional information on the spin-off of their wholly-owned subsidiary, NexPhase Lighting, through a distribution of shares of common stock of NexPhase to the Company's shareholders of record as of October 14, 2012, as announced on September 14, 2012. Onteco reports that they filed the required Information Statement under Section 14(c) of the Securities Exchange Act of 1934, as amended, with the Securities and Exchange Commission (SEC). The Company is currently preparing a response to SEC comments received on the Information Statement.

Onteco has determined that the number of NexPhase Lighting shares to be issued to Onteco shareholders on a pro-rata basis in accordance with their record holdings will be one share of NexPhase Lighting for every 200 shares of Onteco common stock held as of the record date, with fractional shares rounded up to the next nearest share.

We have Onteco Corp. (ONTC) in our sightlines as "One to Watch" this week here at the QualityStocks Daily Newsletter.

Onteco Corp. (ONTC), closed Wednesday’s session at $0.0009, up 12.50%, on 108,297,018 volume with 159 trade. The average volume for the last 60 days is 1,453,627 and the stock's 52-week low/high is $0.0005/$2.70.

Avantair, Inc. (AAIR)

Stock Guru, DrStockPick, PennyOmega, and SmallCapVoice reported earlier on Avantair, Inc. (AAIR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Avantair, Inc. is the industry leader of fractional aircraft ownership in the light jet cabin category. In addition, the Company is the only publicly traded stand-alone private aircraft operator. Avantair is the sole North American provider of fractional shares, leases, as well as flight hour cards in the Piaggio Avanti aircraft. The Company has their headquarters in Clearwater, Florida, and their shares trade on the OTC Bulletin Board.

Avantair offers private travel solutions for individuals and businesses traveling within the Company's service area, at a fraction of the cost of whole aircraft ownership. Avantair's service area includes the continental United States, parts of Canada, the Caribbean and Mexico. Currently, the Company manages a fleet of 57 aircraft.

Avantair (and subsidiaries) provide private aviation services through three primary flight service programs. These are the sale of fractional ownership interests (Fractional Ownership program); the lease of fractional interests (Axis Lease program), and the sale of flight hour cards (Edge Card program and Axis Club Membership program). The Company also manages aircraft fleet; offers aircraft related management and maintenance services; and provides limited fixed based operation services in Clearwater, Florida, and Camarillo, California.  

Last week, Avantair announced financial results for their fiscal 2012 full year and fourth quarter, which ended June 30, 2012. Concerning the Company's Fourth Quarter Fiscal 2012 performance, the total number of revenue-generating flight hours flown for the fourth quarter ended June 30, 2012 increased by 1.0 percent to 11,290. This is in comparison to 11,181 hours flown in the fiscal 2011 fourth quarter. Total revenue for the fourth quarter ended June 30, 2012 decreased 4.3 percent to $42.5 million compared to $44.4 million in the fiscal 2011 fourth quarter.

Net loss attributable to common stockholders for the fourth quarter ended June 30, 2012 was ($2.6) million, or ($.10) per share. This compared with a net loss attributable to common stockholders of ($1.9) million, or ($0.07) per share in the fourth quarter of fiscal 2011.

Concerning Avantair's Full Year Fiscal 2012 performance, the total number of revenue-generating flight hours flown for the fiscal year ended June 30, 2012 increased by 4.8 percent to 45,346. This is compared with 43,278 hours flown in the fiscal year ended June 30, 2011. Total revenue for the fiscal year ended June 30, 2012 grew 6.2 percent to $174.0 million compared to $163.9 million for the fiscal year ended June 30, 2011. Net loss attributable to common stockholders for the fiscal year ended June 30, 2012 was ($8.0) million, or ($.30) per share, This compared to a net loss attributable to common stockholders of ($13.6) million, or ($0.52) per share for the fiscal year ended June 30, 2011.

Yesterday, Avantair announced that they would participate in the COMMIT!Forum conference, taking place October 2-3, 2012 at Cipriani Wall Street, 55 Wall Street, in New York, New York. The conference includes speakers from an array of industries, representing a worldwide commitment to a green environment.

Avantair, Inc. (AAIR), closed Wednesday’s session at $0.34, up 6.25%, on 21,908 volume with 5 trades. The average volume for the last 60 days is 9,767 and the stock's 52-week low/high is $0.28/$1.50.

Manas Petroleum Corp. (MNAP)

UndiscoveredEquities reported last week on Manas Petroleum Corp. (MNAP), Stock Specialists did earlier, and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Founded in 2004, Manas Petroleum Corp. is a global oil and gas company with headquarters in Baar, Switzerland. Their foremost focus is on exploration and development in southeastern Europe, Central Asia, and Mongolia. During their first two years, the Company spent approximately $7 million acquiring and advancing their Kyrgyz, Tajik, and Albanian projects. Their portfolio now totals more than 5 million acres in four countries.

In Albania, Manas Petroleum participates in a 1.7 million acre exploration project via their equity interest in Petromanas Energy, Inc. In the Kyrgyz Republic, Manas signed a US$54 million farm-out agreement with Santos International Holdings Pty Ltd. Santos is a subsidiary of Australia's third largest oil and gas company. In addition to the development of their Kyrgyz Republic project, Santos is developing the Company's neighboring Tajikistan licenses under an option farm out agreement.  

In Mongolia, Manas Petroleum owns record title to the two Production Sharing Contracts (PSCs) covering Blocks XIII and XIV by way of their wholly owned subsidiary DWM Petroleum AG; 26 percent of the beneficial ownership interest in these blocks is held in trust for others. During the first quarter of 2012, Manas Petroleum's Mongolian subsidiary, Gobi Energy Partners LLC, continued with the integration and interpretation of seismic data acquired in 2011. Gobi is currently focusing on six areas with 15 prospects.

The Company's Tajikistan subsidiary, Closed Joint Stock Company Somon Oil, continued with the compilation and integration of their technical database. As of March 31, 2012, a total of 793.6 km of 2D seismic was recorded and processing and interpretations are continuing. Somon Oil finalized the acquisition of 871 km 2D seismic subsequent to March 31, 2012. Drilling planning for the first two wells is ongoing. On May 7, 2012, the Government of the Republic of Tajikistan ratified the Production Sharing Agreement with Somon Oil. Somon Oil is granted the exclusive right and authority to carry out all petroleum exploration, development, as well as production activities in the contract area for a term of 30 years (with the right, under specified circumstances, to renew for up to two additional five-year periods).

In Albania, Manas Petroleum has a 31.7 percent equity interest in Petromanas Energy. Petromanas is entering the operational phase of their drilling program on their Albanian properties. A drilling contract was signed with KCA Deutag.

Yesterday, Manas Petroleum announced that their subsidiary Gobi Energy Partners completed drilling at the Ger Chuluu D1 well. Drilling was stopped after reaching 600 meters without any hydrocarbon shows. After logging, the well was plugged and abandoned. Ger Chuluu D1 was the second well drilled in the Ger Chuluu sub-basin. It was drilled to achieve a final conclusive answer about the potential of this sub-basin. Gobi Energy plans to drill their next well at East Sainshand A prospect. However, because the seasonal window closes at the end of October, the well will be postponed to the next seasonal drilling window.

Manas Petroleum Corp. (MNAP), closed Wednesday’s session at $0.095, down 5.00%, on 318,600 volume with 22 trades. The average volume for the last 60 days is 140,436 and the stock's 52-week low/high is $0.082/$0.34.

Pelangio Exploration, Inc. (PX.V)

MicroCap Gems reported earlier on Pelangio Exploration, Inc. (PX.V), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Pelangio Exploration, Inc. is a junior gold exploration company with corporate headquarters in Milton, Ontario. They acquire and explore camp-sized land packages in premier gold belts. The Company mainly operates in Ghana, West Africa. Pelangio consistently focuses on acquiring large land packages in existing gold camps. Incorporated in 2008, Pelangio Exploration lists on the TSX Venture Exchange.

The Company is exploring two 100 percent-owned camp-sized properties. One is the 100 km2 Manfo Property, the site of five recent near-surface, high grade and bulk tonnage, gold discoveries. The other is the 290 km2 Obuasi Property, located four kilometers on strike and adjacent to AngloGold Ashanti's prolific, high-grade Obuasi Mine, which has produced more than 30 million ounces of gold since 1897.

Ghana is Africa's second-largest gold producing country after South Africa. Almost 60 million ounces of gold have been mined in Ghana over the last century, and Gold reserves and resources are estimated at well over 100 million ounces.
Last week, Pelangio Exploration announced that they identified a new mineralized area at Sika North on the Manfo Project. In addition, the Company provided an exploration update. A seventh area of mineralization was discovered on the Manfo Project at Sika North in diamond drill hole SODD-250, 1.78 grams per tonne (g/t) gold over 15 meters, from 19-34 meters including 6.74 g/t gold over 3.5 meters from 19 metres down-hole. The discovery was drilled within a 700 meter soil geochemical anomaly 3.85 kilometers north of Pokukrom East.

Positive preliminary metallurgical test results show amenability to processing by conventional free milling gold circuit expected to achieve 84 percent to 94 percent recoveries when ground to 80 percent passing 75 micron. The metallurgy is similar to that at some deposits in the region currently in production. A maiden resource estimation is in progress for completion in the first quarter of 2013 covering three areas - Pokukrom East and West, and Nfante West, to include 154 holes totalling 32,333 meters. In total, 78 diamond drill holes (37,313 meters) have been completed since September 2010 at Manfo along a 9 kilometer trend.

At the Obuasi Property a surface exploration program is underway (4,000 samples) covering 10 square kilometers surrounding the North Government area. This is where the most recent drill program encountered high grade results.

Pelangio Exploration, Inc. (PX.V), closed Wednesday’s session at $0.25, up 2.04%, on 102,032 volume. The stock's 52-week low/high is $0.24/$0.64.

Wolverine Exploration, Inc. (WOLV)

OTCPicks and Willy Wizard reported earlier on Wolverine Exploration, Inc. (WOLV), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Wolverine Exploration, Inc. is a junior exploration company that lists on the OTCQB. Wolverine is an exploration stage enterprise engaged in the business of the acquisition and exploration of base and precious metal mineral properties. The Company focuses on the exploration of mineral properties in Labrador, Canada. They hold a 90 percent interest in 429 mineral claims.

Mr. Lee Costerd has been Wolverine Exploration's sole Director and Officer since the Company's establishment on February 23, 2006. Mr. Costerd has been involved in the mining industry for the past 20 years. He was the mine manager for a placer mining operation in British Columbia (BC) and a supervisor at a hard rock mining operation also in BC.

Mr. Ed Montague is the senior geologist for Wolverine Exploration. He is the former representative of the Department of Natural Resources of the provincial government. Mr. Montague was, in part, responsible for the promotion and development of Labrador's mineral resources. He spent 25 years with mining and engineering companies, including Bechtel, Placer Dome, and United Keno Hill. He is a Professional Geoscientist (P. Geo.) registered with the Association of Professional Engineers and Geoscientists of Newfoundland and Labrador. 

Wolverine Exploration's claims cover an area of approximately 10,725 hectares (41 square miles) in central Labrador. The Labrador Claims are located approximately 120 km west of Goose Bay, Labrador. They contain a series of significant copper-gold showings. As pertains to infrastructure and build-out, a year-round road traverses the property. The property is 68 miles to the nearest deep water port. Furthermore, a power line is within easy access and the property has near surface anomalies as well. 

The Company terminated exploratory drilling in October of 2011. There remains seven anomalous areas to be investigated, most of those are 20 km (12.4 miles) west from the 2011 drilling and are centered in the area of all the surface malachite showings which were previously discovered by Wolverine that produced surface copper samples ranging from 2.4 percent Cu to 6.4 percent Cu.

In September, Wolverine Exploration announced their autumn drill program with Innu-Cartwright Drilling from Goose Bay, Labrador. Innu-Cartwright is a well-known local drill rig operator. The full size core drill rig will have the ability to extend the full depth of the magnetic anomaly as discovered by the Ground Induced Polarization survey by Abitibi Geophysics. The exact start date of the program is dependent upon completion of funding. 

Wolverine Exploration, Inc. (WOLV), closed Wednesday’s session at $0.01, up 42.86%, on 250,000 volume with 1 trade. The average volume for the last 60 days is 137,665 and the stock's 52-week low/high is $0.005/$0.054.

The First Marblehead Corp. (FMD)

Today we are highlighting The First Marblehead Corp. (FMD), here at the QualityStocks Daily Newsletter.

Listed on the NYSE, The First Marblehead Corp. helps meet the need for education financing by offering national and regional financial institutions and educational institutions the Monogram® platform. This is an integrated suite of design, implementation, and credit risk management services for private label, customizable, private education loan programs. The Company supports responsible lending and is a strong proponent of the smart borrowing principle, which encourages students to access scholarships, grants, and federally-guaranteed loans before considering private education loans. First Marblehead is based in Boston, Massachusetts. 

The Company, through their subsidiary, Union Federal Savings Bank, offers private education loans, residential and commercial mortgage loans, and retail savings, money market, and time deposit products. First Marblehead also offers outsourced tuition planning, billing, payment technology services, as well as refund management services by way of their subsidiary Tuition Management Systems, LLC.

For Schools, First Marblehead gives colleges and universities the ability to connect students with a spectrum of private student loan options. The Company helps schools ensure that students have the information they need to borrow responsibly. First Marblehead's offering makes it easy for schools to implement programs that meet the unique needs of their student population. 

For Lenders, First Marblehead works with large and small banks and credit unions to design, underwrite, originate, and manage their student loan programs. Their Monogram Platform® offers lenders a branded, outsourced, end-to-end private student loan solution. The design of the Monogram Platform® is to be configurable at each stage in the loan lifecycle.

Today, First Marblehead announced that they signed a definitive agreement to acquire certain assets and liabilities of Cology, Inc., and their affiliates for cash. Cology is a provider of processing, disbursement, and life-of-loan servicing to more than 250 credit unions and lending institutions around the country.

Mr. Daniel Meyers, First Marblehead's Chairman and CEO, said, "Since the financial crisis, credit unions have demonstrated their commitment to financing high quality, credit-tested private student loans. Cology is a rapidly growing private student loan originator that derives the largest share of its business directly from credit unions. We believe that First Marblehead's expertise can help Cology's diverse client base better understand, analyze, control, manage and grow their portfolios."

The First Marblehead Corp. (FMD), closed Wednesday’s session at $1.06, up 1.92%, on 426,283 volume with 1,332 trades. The average volume for the last 60 days is 87,371 and the stock's 52-week low/high is $0.83/$1.52.

Liberty Gold Corp. (LBGO)

Buzz Stocks, The Stock Enthusiast, StreetAuthority Financial, Trade of the Week, ChartPoppers, SmallMovesBigGains, Otcstockexchange, Whisper from Wall Street, and Penny Stocks VIP reported yesterday on Liberty Gold Corp. (LBGO). PennyStockMoney Train, PennyStockPickReport, JediPennyStocks, Winning Penny Stock Picks, WePickPennyStocks, Super Nova Stock Picks, Super Hot Penny Stocks, PennyStockPickAlert, and Liquid Tycoon also reported this week, and we highlight the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Bulletin Board, Liberty Gold Corp. is a gold and precious metals exploration company. The Company's ongoing property acquisition strategy targets regions with proven gold and silver resources and industry-friendly business environments. Their project portfolio includes the Domestic Portfolio in Arizona and the McCord Creek Property in Alaska. Liberty Gold has their headquarters in Phoenix, Arizona.

The Company has a 100 percent interest in the 794-acre Domestic Portfolio mining operations claim block. It is located in the Cerbat Mountain range, approximately 75 miles southeast of Las Vegas and 15 miles northwest of Kingman in northwestern Arizona's Wallapai Mining District. In August, Liberty Gold announced positive results following initial sampling and processing for visible gold on their Domestic Portfolio.

Liberty Gold's ongoing 2012 McCord Creek work program has collected and submitted 333 samples for analysis. The objective is defining drill targets for the 2013 field season.

This week, Liberty Gold reported on International Tower Hill's (ITH) August 21, 2012 announcement of new, high-grade gold intercepts surrounding ITH's main deposit at their Livengood Gold Project in Alaska. ITH's Livengood Property immediately adjoins the western side of Liberty Gold's 4,620-acre McCord Creek Property. The Money Knob deposit on ITH's Livengood Property represents a resource estimate of 16.5 million ounces (Moz) Measured & Indicated at 0.22 grams per tonne cut-off, making it one of the largest gold deposits discovered in 20 years.

Immediately adjoining the eastern side of ITH's Livengood Property is Liberty Gold's McCord Creek Property, located in the eastern extension of the Livengood gold district. A work program in 2011 resulted in the discovery of 5 gold-in-soil anomalous zones on the McCord Creek Property with the maximum soil value exceeding 100 parts per billion (ppb) gold.

Lynn Harrison, Liberty Gold's President and CEO, commented: "International Tower Hill's latest drill results underscore the gold potential of the Livengood district. The news only increases our interest in receiving the results from our 2012 work program on our adjoining McCord Creek Property."

Liberty Gold Corp. (LBGO), closed Wednesday’s session at $0.459, down 2.34%, on 63,076 volume with 48 trades. The average volume for the last 60 days is 71,077 and the stock's 52-week low/high is $0.20/$1.15.

Lightlake Therapeutics, Inc. (LLTP)

SmallCapVoice, Bull Warrior Stocks, Market FN, The Best Newsletters, AnotherWinningTrade, SmallCapVoice, Forbes, Stockoutlaws, OTCPicks, and Hidden Values Alert reported earlier on Lightlake Therapeutics, Inc. (LLTP), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Trading on the OTCQB, Lightlake Therapeutics, Inc. is an early stage biopharmaceutical company. They are using their expertise in opioid antagonists to develop innovative treatments for common addictions and related disorders. Currently, the Company is focusing on developing a treatment for overweight and obese patients with Binge Eating Disorder (BED), and a treatment for patients with Bulimia Nervosa. Lightlake Therapeutics' is based in London, England. 

This year, the Company completed a Phase II clinical trial in Helsinki, Finland to investigate the use of the opioid antagonist naloxone delivered intra-nasally as a treatment for Binge Eating Disorder (BED). BED is a psychiatric condition that is manifested by recurrent episodes of eating unusually large amounts of food in a short period of time associated with a sense of lack of control over food intake. 

The science Lightlake Therapeutics is using to develop a treatment for Binge Eating Disorder is derived from the "Sinclair Method," for the treatment of alcohol dependency, which was developed by the Company's Chief Science Officer, Dr. David Sinclair.

In August, Lightlake Therapeutics announced persuasive final data from a Phase II study of their proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED). Patients receiving the naloxone nasal spray achieved the study's primary endpoint by exhibiting a statistically significant reduction in time spent per week binge eating compared to those patients who received a placebo nasal spray, reducing their bingeing by 125 minutes per week, in comparison to 84 minutes per week for placebo-treated subjects (p=0.024). The Phase II study was a randomized, double-blind, placebo-controlled, six-month study of intranasal naloxone in men and women with BED. The trial enrolled 127 patients and took place in Helsinki, Finland, between August 2011 and March 2012.

Recently, Lightlake Therapeutics announced that they appointed former U.S. Food and Drug Administration Commissioner, Dr. David Kessler, as a strategic advisor. Dr. Kessler was the FDA Commissioner under Presidents George H. W. Bush and Bill Clinton, where he directed a number of new programs.

Lightlake Therapeutics, Inc. (LLTP), closed Wednesday’s session at $0.153, up 2.00%, on 271,561 volume with 4 trades. The average volume for the last 60 days is 229,041 and the stock's 52-week low/high is $0.043/$0.55.

graphic

The QualityStocks
Company Corner

graphic
graphic

MusclePharm Corp. (MSLP)

The QualityStocks Daily Newsletter would like to spotlight MusclePharm Corp. (MSLP). Today, MusclePharm Corp. closed trading at $0.0057, off by 1.72%, on 13,552,120 volume with 71 trades. The stock’s average daily volume over the past 60 days is 4,773,102, and its 52-week low/high is $0.0055/$0.0375.

MusclePharm Corp. announced winning three out of the 23 top honors at this year's Bodybuilding.com Supplement Awards, September 29-30th at the 2012 Joe Weider's Olympia in Las Vegas, largely thanks to massive support directly from the Internet votes cast by enthusiastic consumers loyal to the brand. MusclePharm took home Brand of the Year, Pre-Workout Supplement of the Year for Assault™, and Packaging of the Year, beating out the field of some 70 nominations (selected based on sales) drawn from over 500 brands, 235 different pre-workout products, and 8k health and fitness products available through Bodybuilding.com, helping to break the record this year for number of votes cast (2.4M total).

MusclePharm Corp. (MSLP) is focused on providing a full line of Informed Choice-approved nutritional supplements that not use any substances banned in the sports industry. Now sold in more than 120 countries and available in over 10,000 U.S. retail outlets, the company's products address all categories of an active lifestyle, including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen.

Current CEO Brad Pyatt founded the company to develop a superior line of nutritional supplements that would help fellow athletes improve their performance in a way that existing supplements did not. Even as the company has grown, its mission has remained the same: to improve its customers' lives, increase their ability to excel, use cutting-edge science to develop the best nutritional supplements on the market, and provide a safe option for athletes.

MusclePharm's products were developed through exhaustive research at the MusclePharm Sports Science Center Research Institute. New products are created through a six-stage research protocol that involves the expertise of top nutritional scientists. Before launching a product, the company conducts field testing using a pool of over one hundred elite professional athletes from various professional sports leagues, including the National Football League, Mixed Martial Arts, and Major League Baseball.

Over the last few years, the consumption of sports nutrition products has shifted to mainstream consumers who have become the key drivers of growth within the industry. Teenagers and college students, women, and even older individuals are now using these products to help them live a more active and healthier lifestyle. With a full line of supplements and an extensive distribution network, MusclePharm is well positioned to capitalize on the growing demand. Disclaimer

MusclePharm Corp. Company Blog

MusclePharm Corp. News:

MusclePharm Wins Three Prestigious Bodybuilding.com Awards, Including Brand of the Year, Upon Fitness Enthusiasts' Votes

MusclePharm Adds Dick's Sporting Goods To Its Growing Retail Distribution

United States Sports Academy Researchers Present Clinical Trial Results For MusclePharms' Assault™ Pre-Workout

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.0030, up 50.00%, on 340,200 volume with 12 trades. The stock’s average daily volume over the past 60 days is 163,049, and its 52-week low/high is $0.001/$0.018.

Consorteum Holdings, Inc. (CSRH) utilizes the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create customized programs for maximum results. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.

Through its exclusive software license with Tarsin Inc., the company leverages a team of software developers that understands the complexities of delivering digital media content across mobile handsets. Tarsin is capable of providing clients with integration and support for over 700 mobile carriers globally on a seamless and secure platform to take advantage of the increasing demand for rich mobile content.

Consorteum's flagship CAPSA technology platform brings a universal solution to the problems of wagering and betting on mobile devices. Multiple different operating systems, user interfaces, and form factors have created enormous barriers to launching commercial initiatives. But with CAPSA, gaming operators can now cost-effectively monetize innovative mobile wagering products and services quickly and robustly.

In addition to its mobile initiatives, Consorteum is also actively engaged in the financial industry, providing MasterCard solutions as well as loyalty and reward programs. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

CORRECTION -- Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming

Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming

Consorteum Completes Acquisition of Tarsin Inc.

TNI BioTech, Inc. (TNIB)

The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $2.00, up 33.33%, on 176,661 volume with 109 trades. The stock’s average daily volume over the past 60 days is 23,478, and its 52-week low/high is $0.72/$10.01.

TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.

The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.

Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.

The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer

TNI BioTech, Inc. Company Blog

TNI BioTech, Inc. News:

TNI BioTech Signs Agreement With Government of Malawi to Open an Oncology & Infectious Disease Clinic at Queen Elizabeth Central Hospital

TNI BioTech, Inc. Signs Memorandum of Agreement to Open Pharmaceutical Plant for the Production of IRT-103 (LDN)

Dr. Ronald Herberman Joins TNI BioTech Inc. as Senior Vice President of Research and Development and Chief Medical Officer

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.80, even for the day, on 500 volume with 1 trade. The stock’s average daily volume over the past 60 days is 37, and its 52-week low/high is $0.06/$3.15.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

VistaGen's lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Therapeutics Announces Strategic Financing With Platinum Long Term Growth Fund

VistaGen CEO Issues Update Letter to Stockholders

VistaGen Secures Key U.S. Patent Covering Stem Cell Technology Methods Used to Test Drug Candidates for Liver Toxicity

VistaGen Therapeutics, Inc. (VSTA) is “One to Watch”

VistaGen Therapeutics is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants (“drug rescue variants”) of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen’s versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen’s human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

VistaGen’s lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen’s development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington’s Disease and Parkinson’s disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform.

For additional information, visit the company’s website at www.VistaGen.com

MusclePharm Corp. (MSLP) Wins Multiple Bodybuilding.com Awards; Fitness Enthusiasts Praise Nutritional Supplements

MusclePharm, a healthy lifestyle company that develops and manufactures nutritional supplements, announced this morning that it has been awarded three of the 23 top honors at the 2012 Bodybuilding.com Supplement Awards, awarded last week at the 2012 Joe Weider’s Olympia in Las Vegas, Nevada.

The awards reflected votes casted by consumers, with over 500 brand names and more than 8,000 health and fitness products competing for recognition. The original 70 nominations this year were based on sales, and consumers voted from July 13 – August 31, 2012, in picking this year’s final winners. According to today’s press release, there were a record-breaking number of votes totaling 2.4 million.

The awards won by MusclePharm include:

• Brand Of the Year
• Pre-Workout Supplement Of the Year (AssaultTM)
• Packaging of the Year

“MusclePharm is especially gratified to receive these prestigious awards, because workout enthusiasts cast the votes for what they feel are the best products,” stated MusclePharm Chief Executive Officer Brad Pyatt. “We were honored to win these three awards, and with a field of over 8,000 supplements—235 different pre-workout products challenging our Assault™ pre-workout alone—we are proud to be a standout brand in the eyes of the consuming public. To our customers, a big thanks from the entire MP Team!”

For additional information, visit the company’s website at www.MusclePharm.com

Skinny Nutritional Corp. (SKNY) Management Proves Ability to Rapidly Boost Market Presence

Skinny Nutritional, provider of the only true zero calorie, sugar, carb, sodium, and preservative-containing beverage available, continues Mid-Atlantic market penetration. The company, maker of Skinny Water, recently announced that the product is now available in 275 store locations throughout the region. Skinny Water can be found under the A&P retail banner of stores, including Pathmark, Superfresh, Waldbaum’s, and A&P.

Joseph Gisondi, VP of National Retail Sales, stated, “Skinny Nutritional Corp. and A&P look forward to building and cultivating the Skinny Water brand through various advertising mediums which will include circular/ad sales, displays, sampling events and joint promotions.” Skinny Water is currently available in over 14,275 retail stores nationwide.

The company’s strong emphasis on health, fitness, and community has served marketing initiatives very well. The new age beverage segment has seen increasing momentum in recent years, with just about every beverage company getting into the game, but none of them has the kind of no-nonsense product composition behind Skinny Water, something that appeals directly to the majority of the core consumer market.

Featuring educational materials at point of sale, Skinny Nutritional continues with the introduction of its new product, Skinny Water pH+, as well. Inspired by the alkaline diet favored by celebrities and medical practitioners, and delivering on the belief that the human body should maintain an optimum balance of acidity and alkalinity, Skinny Water pH+ is infused with minerals to help keep the body balanced. Fortified with magnesium, zinc, and potassium found in fruits and vegetables, an alkaline diet is believed to greatly benefit overall well-being by providing increased levels of energy, and even clearer skin, increased metabolism, and mental clarity.

For additional information, visit the company’s websites at www.SkinnyWater.com

Biostar Pharmaceuticals, Inc. (BSPM) Signs Agreement to Manufacture and Supply Three New Drugs to Xijing Military Hospital

Biostar Pharmaceuticals has announced that on Sept. 24, the company signed a one-year agreement to manufacture and supply three new drugs to Xijing Hospital: Gastritis Granule, Pharyngitis Granule, and Nasosinusitis Granule.

Valued at approximately $3.6 million (RMB 24 million), the agreement will take effect this month. Beginning in October, Biostar will deliver its first monthly supply (valued at around $0.3 million, or RMB 2 million) to Xijing Hospital. To be sold exclusively at Xijing Hospital, the three drugs will be given to patients admitted to the hospital for treatment. Gastritis Granule is used for the treatment of chronic and atrophic gastritis; Pharyngitis Granule is used for the treatment of acute and chronic throat inflammation; and Nasosinusitis Granule is used for the treatment of acute and chronic sinusitis.

A military hospital managed by The Fourth Military Medical University (FMMU), Xijing Hospital is one of China’s prominent military medical universities and research centers. Notably, Biostar was chosen as one of only nine pharmaceutical companies in China to work with FMMU in the fields of research and product development. Since being selected, Biostar has been working closely with FMMU’s staff to implement experimental product tests covered under the corporation agreement, including tests for Gastritis Granule, Pharyngitis Granule, and Nasosinusitis Granule.

Biostar was able to speedily and successfully complete experimental tests and trial production for all three products. Once the products passed manufacturing technology and quality inspections, the company purchased raw materials to begin production and is currently manufacturing all three drugs to be sold exclusively to Xijing Hospital, in accordance with the agreement.

Biostar will continue working with FMMU’s staff to share resources and ideas and to carry out clinical trials for other new products, which will aid the company in becoming a production base for manufacturing drugs specifically to meet the needs of China’s military. The company hopes to further expand its relationship with Xijing Hospital for more than a dozen other new drugs, which Biostar currently has technology to manufacture at its facilities.

Biostar Pharmaceuticals, through its wholly owned subsidiary and controlled affiliate in China, is engaged in developing, manufacturing, and marketing pharmaceutical and health supplement products for various diseases and conditions. Xin Aoxing Oleanolic Acid Capsule, an OTC medicine for treating chronic hepatitis B, is the company’s lead product.

For more information, visit the company’s Web site at www.biostarpharmaceuticals.com

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

OTCPicks
(ALTO)

2.

Greenbackers
(SRPT)

3.

Wall Street Resources
(TBUSQ)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251